Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hapten inhibition and dextran anaphylaxis.

K G Ljungström1, H Renck, H Hedin

  • 1Department of Surgery, Danderyd Hospital, Sweden.

Anaesthesia
|September 1, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Future orthopedic training, a global watch.

Acta orthopaedica·2013
Same author

Presenilin-1 in neuroblastoma cells.

Toxicology in vitro : an international journal published in association with BIBRA·2010
Same author

An evaluation of computer-aided disproportionality analysis for post-marketing signal detection.

Clinical pharmacology and therapeutics·2007
Same author

Drug-attributed anaphylaxis.

Pharmacoepidemiology and drug safety·2004
Same author

[A promising start for quality indicator work within vascular surgery?].

Lakartidningen·2002
Same author

Identification of sulfonamide-like adverse drug reactions to celecoxib in the World Health Organization database.

Current medical research and opinion·2002

Hapten inhibition using dextran 1 significantly reduced severe anaphylactic reactions to dextran in Sweden. This preventive measure dramatically lowered both severe and fatal reactions, improving patient safety.

Area of Science:

  • Immunology
  • Pharmacology
  • Clinical Medicine

Background:

  • Dextran administration can cause severe anaphylactic reactions.
  • Preventive strategies are crucial for safe dextran use in medical settings.

Observation:

  • Hapten inhibition with dextran 1 was implemented in Sweden in 1982.
  • Over 600,000 units of dextran were used in both pre- and post-intervention periods.

Findings:

  • Severe dextran reactions decreased from 22 to 1.2 per 100,000 units used.
  • Fatal dextran reactions dropped from 23 to one case.

Implications:

  • Hapten inhibition is a highly effective method for preventing dextran-induced anaphylaxis.
  • This approach significantly enhances patient safety during dextran therapy.

Related Experiment Videos

  • The findings support the widespread adoption of hapten inhibition protocols.